Literature DB >> 27586078

Combined treatment with X-ray irradiation and 5-aminolevulinic acid elicits better transcriptomic response of cell cycle-related factors than X-ray irradiation alone.

Junko Takahashi1, Masaki Misawa2, Hitoshi Iwahashi3.   

Abstract

PURPOSE: 5-Aminolevulinic acid (ALA) is a precursor of the photosensitizer protoporphyrin (PpIX) used in photodynamic therapy. In our previous work, PpIX enhanced the generation of reactive oxygen species by X-ray irradiation. In this study, we evaluated the potential of ALA as an endogenous sensitizer to X-ray irradiation.
METHODOLOGY: Tumor-bearing C57BL/6J mice implanted with B16-BL6 melanoma cells were subsequently treated with irradiation (3 Gy/day for 10 days; total, 30 Gy) plus local administration of 50 mg/kg ALA 24 hours prior to each irradiation (ALA-XT). Tumor-bearing mice without treatment (NT), those treated with ALA only (ALAT), and those treated with X-ray irradiation only (XT) were used as controls.
RESULTS: ALA potentiated tumor suppression by X-ray irradiation. In microarray analyses using tumor tissue collected after 10 sessions of fractional irradiation, functional analysis revealed that the majority of dysregulated genes in the XT and ALA-XT groups were related to cell-cycle arrest. Finally, the XT and ALA-XT groups differed in the strength of expression, but not in the pattern of expression.
CONCLUSIONS: mRNA analysis revealed that the combined use of ALA and X-ray irradiation sensitized tumors to X-ray treatment. Furthermore, the present results were consistent with ALA's tumor suppressive effects in vivo.

Entities:  

Keywords:  5-aminolevulinic acid (ALA); Radiotherapy; X-ray; mouse caner model; protpporphyrin IX (PpIX); sensitizer

Mesh:

Substances:

Year:  2016        PMID: 27586078     DOI: 10.1080/09553002.2016.1230240

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  6 in total

Review 1.  Deep-Tissue Activation of Photonanomedicines: An Update and Clinical Perspectives.

Authors:  Nimit Shah; John Squire; Mina Guirguis; Debabrata Saha; Kenneth Hoyt; Ken Kang-Hsin Wang; Vijay Agarwal; Girgis Obaid
Journal:  Cancers (Basel)       Date:  2022-04-15       Impact factor: 6.575

2.  Verification of radiodynamic therapy by medical linear accelerator using a mouse melanoma tumor model.

Authors:  Junko Takahashi; Mami Murakami; Takashi Mori; Hitoshi Iwahashi
Journal:  Sci Rep       Date:  2018-02-09       Impact factor: 4.379

3.  An Orthotopic Model of Glioblastoma Is Resistant to Radiodynamic Therapy with 5-AminoLevulinic Acid.

Authors:  Charles Dupin; Jade Sutter; Samuel Amintas; Marie-Alix Derieppe; Magalie Lalanne; Soule Coulibaly; Joris Guyon; Thomas Daubon; Julian Boutin; Jean-Marc Blouin; Emmanuel Richard; François Moreau-Gaudry; Aurélie Bedel; Véronique Vendrely; Sandrine Dabernat
Journal:  Cancers (Basel)       Date:  2022-08-31       Impact factor: 6.575

4.  Radiodynamic Therapy Using TAT Peptide-Targeted Verteporfin-Encapsulated PLGA Nanoparticles.

Authors:  Sandhya Clement; Ayad G Anwer; Layla Pires; Jared Campbell; Brian C Wilson; Ewa M Goldys
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

5.  DNA Strand Break Properties of Protoporphyrin IX by X-Ray Irradiation against Melanoma.

Authors:  Takema Hasegawa; Junko Takahashi; Shinsuke Nagasawa; Motomichi Doi; Akihiro Moriyama; Hitoshi Iwahashi
Journal:  Int J Mol Sci       Date:  2020-03-26       Impact factor: 5.923

6.  Verification of 5-Aminolevurinic Radiodynamic Therapy Using a Murine Melanoma Brain Metastasis Model.

Authors:  Junko Takahashi; Shinsuke Nagasawa; Mitsushi J Ikemoto; Chikara Sato; Mari Sato; Hitoshi Iwahashi
Journal:  Int J Mol Sci       Date:  2019-10-17       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.